News Article

Hiroyoshi Nishikawa Honoured with the 2020 SITC 'Team Science Award'

Dr Hiroyoshi Nishikawa, Professor - Department of Immunology, Nagoya University Graduate School of Medicine  (Chief -Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center) was conferred the 2020 SITC Team Science Award. The honour was in recognition to his work as a member of the team lead by the late Lloyd J. Old, MD, who established the research field of cancer immunology.

The Society for Immunotherapy of Cancer (SITC) is the world’s leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy.
The winner of the 2015 was Dr James Allison’s group which won the 2018 Novel Prize in Physiology or Medicine with Dr Tasuku Honjo, Deputy Director-General and Distinguished Professor, Institute for Advanced Study Kyoto University.
https://www.sitcancer.org/funding/awards/anniversaryawards/sitc2015

SITC 35th Anniversary Awards
https://www.sitcancer.org/funding/awards/anniversaryawards/sitc2020

 

nishikawa201117.jpgHiroyoshi Nishikawa, MD. PhD.

Research Achievements
Dr. Nishikawa has studied the mechanisms by which the immunosuppressive network, including CD4+ regulatory T (Treg) cells, suppresses anti-tumor immune responses, and has also been developing therapeutic strategies to overcome these mechanisms. In particular, he found the typical phenotypes of effector T cells, which are important for anti-tumor immune responses, that are suppressed by Treg cells depending on the nature of the antigen (exhaust for non-self and anergy for self-antigens). These findings are extremely important for understanding not only tumor immunity, but also various immune responses such as autoimmunity, allergy, infection and transplantation. In addition, he has recently proposed a novel concept in the carcinogenic process in which genomic aberrations of cancer cells affect the immune response and establish an immunosuppressive network in the tumor microenvironment, and commits to develop immunogenomic precision medicine.

Positions and Employment
1989-1995: Mie University School of Medicine, M.D., Mie, Japan
1995: Junior Resident, Mie University Hospital, Mie, Japan
1995-1997: Junior Resident, Matsusaka-Chuo General Hospital, Mie, Japan
1997-1998: Senior Resident, Hematology/Oncology Section, Suzuka General Hospital, Mie, Japan
1998-2002: Mie University Graduate School of Medicine, Ph.D., Mie, Japan
2002-2003 Fellow, Department of Hematology/Oncology, Mie University Hospital, Mie Japan.
2003-2006 Research fellow, Memorial Sloan Kettering Cancer Center, New York, NY
2006-2010 Assistant Professor, Department of Cancer Vaccine, Mie University, Graduate School of Medicine, Mie, Japan
2010-2015 Associate Professor, Experimental Immunology, IFReC, Osaka University, Osaka, Japan
2012-2015 Adjunct Associate Professor, Department of Oncology, Roswell Park Cancer Institute, Buffalo, NY
2015-present Chief, Division of Cancer Immunology, Research Institute / EPOC National Cancer Center, Tokyo/Chiba, Japan
2016-present Professor, Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan


Immunology, Oncology, particularly Tumor Immunology